GLP2-T

About GLP2-T

GLP2-T was originally developed to treat Type-2 diabetes but has since become a leading anti-obesity compound. It is a dual agonist of the GLP-1 and GIP receptors — activating two distinct hormonal pathways to reduce appetite, improve metabolic rate, and support sustained weight loss. GLP-1 suppresses appetite and increases feelings of fullness after eating, while GIP promotes insulin secretion and supports energy balance through receptors in the hypothalamus. Unlike its predecessor GLP1-S (which targets GLP-1 only), GLP2-T showed 5–7% more weight loss in clinical trials. Compared to GLP3-R, a triple agonist, GLP2-T accomplished nearly the same weight loss but over a longer period (72 weeks vs. 48).

Dosing & Reconstitution Guide

Starting dose:

• If you have never taken ANY GLP: your starting dose is 2.5 mg per week.
• If you have previously taken any GLP for at least one month at the standard starter/adaptive dose — no matter how much time has elapsed since — your starting dose is 5 mg per week.

— 10 mg Vial —

Reconstitute: Mix with 0.5 mL (50 units) of BAC water → 20 mg/mL concentration.
Administration: Subcutaneous injection.
Timing: Dose once per week (every 7 days), always on the same day of the week. May be taken at any time of day/night; fasting is not required.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, avoid freeze-thaw cycles.

Schedule: One dose every 7 days. You must remain on each dose for a minimum of 4 weeks before moving to the next dose.
Goal: Appetite reduction, improved insulin sensitivity, and sustained weight loss.

Dose	Syringe (U-100)
2.5 mg	12 units
5 mg	25 units
7.5 mg	36 units
10 mg	50 units

— 30 mg Vial —

Reconstitute: Mix with 1.5 mL (150 units) of BAC water → 20 mg/mL concentration.
Administration: Subcutaneous injection.
Timing: Dose once per week (every 7 days), always on the same day of the week. May be taken at any time of day/night; fasting is not required.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, avoid freeze-thaw cycles.

Schedule: One dose every 7 days. You must remain on each dose for a minimum of 4 weeks before moving to the next dose.
Goal: Appetite reduction, improved insulin sensitivity, and sustained weight loss.

Dose	Syringe (U-100)
2.5 mg	12 units
5 mg	25 units
7.5 mg	36 units
10 mg	50 units
12.5 mg	62 units
15 mg	75 units

— 60 mg Vial —

Reconstitute: Mix with 2.5 mL (250 units) of BAC water → 24 mg/mL concentration.
Administration: Subcutaneous injection.
Timing: Dose once per week (every 7 days), always on the same day of the week. May be taken at any time of day/night; fasting is not required.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, avoid freeze-thaw cycles.

Schedule: One dose every 7 days. You must remain on each dose for a minimum of 4 weeks before moving to the next dose.
Goal: Appetite reduction, improved insulin sensitivity, and sustained weight loss.

Dose	Syringe (U-100)
2.5 mg	10 units
5 mg	21 units
7.5 mg	31 units
10 mg	42 units
12.5 mg	52 units
15 mg	62 units

Benefits

• Average weight loss of 24.7% after 72 weeks in clinical trials.
• Reduces appetite and cravings.
• Enhances satiety and energy balance.
• Supports fat oxidation and metabolism.
• Improves insulin sensitivity and blood sugar control.

Side Effects

Side effects are often mild and temporary; they affected only ~25% of participants in trials:

• Injection site reaction (redness, swelling, itching)
• Nausea
• Vomiting
• Diarrhea
• Constipation
• Decreased appetite
• Fatigue
• Dyspepsia (indigestion)
• Abdominal pain
• Burping (may have sulfur smell)
• Hair loss

Rare but serious risks:

• Thyroid C-cell tumors
• Pancreatitis
• Gastroparesis (stomach paralysis)
• Hypoglycemia (if used with insulin)
• Gallbladder disease
• Kidney issues (linked to dehydration)
• Pulmonary aspiration under anesthesia — ALWAYS disclose GLP2-T use to surgical teams

Interactions

Drug & lifestyle interactions:

• Insulin and insulin-stimulating drugs – Includes all forms of insulin, sulfonylureas (glipizide, glyburide, glimepiride), and glinides (repaglinide), due to the increased risk of hypoglycemia
• Oral medications – GLP2-T may interfere with the absorption of oral medications
• Oral birth control – Increases the likelihood of additive GI effects, may lead to excessive appetite suppression, and increases hypoglycemia risk
• Growth hormone / GH analogs – Interactions reported with somatropin, lonapegsomatropin, somapacitan
• Alcohol – Increases the risk of hypoglycemia and worsens nausea and dehydration
• Dehydration risk – Places excessive stress on the kidneys and may lead to kidney damage; risk increases with concurrent ACE inhibitors, diuretics, ARBs, and heart failure regimens
• Berberine / Metformin – Increased risk of hypoglycemia
• Chromium / insulin sensitizers – Increased risk of hypoglycemia
• Appetite suppressants – Added risk of eating disorder/anorexia
• Stimulants – Excessively diminished appetite and GI intolerance overlap
• Large, greasy meals – Increase the likelihood of nausea

Peptide interactions — SEVERE:

• Other GLP peptides – Receptor redundancy and desensitization
• Tesamorelin – Elevated glucose levels
• IGF-1 LR3/DES and strong ghrelin agonists (e.g. GHRP-2 and GHRP-6) – May oppose or significantly amplify GLP2-T’s metabolic signaling

Peptide interactions — MODERATE:

• IGF-1 LR3 and IGF-1 DES – Risk of hypoglycemia and rapid glucose uptake
• CJC with DAC – Blunts GLP metabolic benefit
• GHRP-2, GHRP-6, Hexarelin – Can counter appetite suppression
• BAM-15 – Watch appetite suppression and fatigue
• LL-37 – May worsen nausea and inflammation
• Oxytocin – Monitor excessive appetite loss

Contraindications

• Do not use if pregnant or breastfeeding.
• Do not use with a personal or family history of Medullary Thyroid Carcinoma or MEN 2 (Multiple Endocrine Neoplasia).
• Do not use if you have Type-1 diabetes, diabetic retinopathy, or severe GI disease.
• Do not use if you are allergic or hypersensitive to GLP2-T.

Stacking Suggestions

Common research pairings with GLP2-T include:

• AOD-9604 – Enhances fat breakdown and further accelerates weight loss alongside appetite suppression
• Tesamorelin – Synergistic for fat reduction, especially visceral fat and metabolic regulation (note the glucose interaction above)
• Semax or Selank – Manage mood and cognitive function while adjusting to appetite changes
• NAD+ or MOTS-C – Support energy, mitochondrial efficiency, and metabolism while on a caloric deficit
• BPC-157 – Beneficial for gut repair if experiencing nausea, indigestion, or stomach discomfort
• CJC No DAC / Ipamorelin – For muscle maintenance and enhanced metabolic recovery while losing fat

Research Sources

Citations for verification. Many studies are animal/in-vitro.

1. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1 trial). N Engl J Med. 2022;387(3):205-216. PMID: 35658024
2. Frías JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. PMID: 34170647